Melior Discovery
home
Our Services
High Throughput In Vivo Pharmacology:
Our Technology
 

theraTRACE

Melior Pharmaceuticals

             

 

             

 

 

                 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery management team


melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsy   Andrew G. Reaume, Ph.D., MBA
   President and CEO, Co-Founder

   Dr. Reaume has been responsible for building a robust, proprietary, clinical
   candidate pipeline for Melior while simultaneously attracting the partnership
   of many of the leading global pharmaceutical companies through Melior’s
   capabilities with in vivo profiling.


Dr. Reaume was previously a Senior Business Analyst at Pfizer, Inc. in the department of genomics and proteomic sciences.  While at Pfizer, he conceived of the idea to create a platform for comprehensively characterizing (phenotyping) genetically modified mice.  He subsequently spearheaded the initiative to build it with a third party collaborator by working closely with scientists throughout the global Pfizer organization, business development professionals, information technology specialists as well as the scientists and business development professionals at the partner company.

 

From 1993 to 1999 Dr. Reaume worked in R&D at Cephalon where he was principally involved in creating animal models of neurodegenerative disease.  In addition to Dr. Reaume’s research activities, at Cephalon he identified and helped coordinate in-licensing opportunities. 

 

In 2003, he received his MBA from the Wharton School where he graduated with honors in Entrepreneurial Management.  He received his PhD in genetics from the University of Connecticut in 1990.

 

melior 

 

                                                melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE             
   Patty Ferrante

  Chief Operating Officer

   Patty has a leadership role in many aspects of Melior's day-to-day operations
   including the implementation, reporting, and oversight of the company's
   financials. She also manages human resources, client services, and
   information technology.
  
   Prior to joining Melior in 2007, Patty held leadership roles in the transportation
   industry with prominent local agents for United Van Lines and Mayflower Transit.

 

She comes to Melior with over 20 years of experience in project management, finance, customer services, and sales management.  Patty received her Bachelor of Arts degree in Management Marketing from Holy Family University in Philadelphia, PA.  When not working, she enjoys spending time with her family, gardening and the beach.

 

 

melior

           

 melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton penns   Ramana Kuchibhatla, Ph.D.
   Senior VP of Clinical Development & Biostatistics

   Dr. Ramana Kuchibhatla received a B.Sc. {Hons} in Mathematics and a M.Sc.
   in Applied Statistics from the Osmania University in Hyderabad, India.  He
   worked at ICMR’s Institute for Research in Medical Statistics in Madras in
   public health and health statistics before joining the Administrative Staff
   College of India in Hyderabad as a Faculty Member in the Center for Energy,
   Environment & Technology. 

He joined the University of Iowa Graduate Program in Geography to major inQuantitative Methods and Environmental Studies.  He received his M.A. and Ph.D. from the University of Iowa, Iowa City, IA, USA.  Subsequently, he worked at ManTech Environmental Technology, Inc. a private consulting company specializing in environmental and health assessments where he studied cancer risks of agricultural chemicals. 

 

His pharmaceutical career spans nearly 20 years starting with Glaxo Wellcome (now GlaxoSmithKline) where he consulted in Biostatistics and later in Clinical Research and Development in the Neurology & Psychiatry therapeutic area.  During his tenure, he was involved in the successful filing of two sNDAs that brought Zyban® and Lamictal® (pediatric indication) to market.  In 2001, he joined Targacept, Inc. as Sr. Director of Clinical Research and Development to help setup Clinical Development, Biostatistics and Data Management functions at Targacept Inc.  Dr. Kuchibhatla helped file several INDs for various neuropsychiatric indications as well as bring several NCEs into clinical development with trials conducted in North America, UK, Eastern Europe, and India.  He was closely involved in several successful in-licensing and out-licensing deals Targacept and played a critical role in their successful IPO in June 2006.

 

In April 2007, Dr. Kuchibhatla left Targacept and founded QED Pharmaceutical Services with offices in North Carolina, USA and in Hyderabad, India to offer integrated clinical research consulting services to the pharmaceutical companies. He helped several companies plan and implement clinical development and regulatory activities in USA, Europe (both Eastern and western), and India over the past 9 years.



melior


melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE Gennady N. Smagin, MD, Ph.D.
Director of Pharmacology

  

Dr. Smagin is a Director of Pharmacology at Melior.  He specializes in working with clients to custom-design experiments to evaluate therapeutic efficacy in models of anxiety, depression, sleep/wake (qEEG), and EEG-based seizure activity. He has a broad background and experience in functional neuroanatomy and neurochemistry as well as translational biomarkers for target-based pharmacology and safety assessments.  Dr. Smagin is proficient in working with and managing external collaborators, contract research organizations and non-profit organizations.

 

Prior to joining Melior he worked at Lundbeck Research USA and AstraZeneca Pharmaceuticals (CNS/Psychiatry discovery) for >15 years where he designed and supervised neurochemical and pharmacological studies involving numerous disease areas, including evaluation of depression, anxiety, Parkinson’s (PD) and Alzheimer’s  (AD) diseases and neurodegeneration.

 

Dr. Smagin received his medical training (MD) from Siberian Medical University (USSR) and a Ph.D. from Pavlov Institute of Experimental Medicine (St.Petersburg, Russia). He studied the neurochemistry and neuroendocrinology and neuroimmunology of stress-related disorders. As a postdoctoral fellow and later faculty member at LSU Medical Center in Shreveport, he studied neuroendocrinology of stress and its role in obesity, food intake and addiction.  Dr. Smagin authored and co-authored over 40  peer-reviewed publications in various areas of neuropharmacology and neuropsychiatry including neurodegenerative diseases, AD, depression, anxiety and schizophrenia.  Dr. Smagin has regulatory and compliance knowledge, including membership on the Institutional Animal Care and Use committee.

 


melior

                                                    melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE             
   John A. Gruner, Ph.D.

   Director of Neurophysiology

   Dr. Gruner directs all neurophysiology studies at Melior.  He specializes in
   working with clients to custom-design experiments to evaluate therapeutic
   efficacy in models of motoneuron disease (e.g. G93A transgenic SOD mice),
   neurotrauma, pain and muscle relaxation (nociceptive and proprioceptive spinal
   reflexes and neuromuscular function), sleep / wake and general cortical function
   (including high-frequency EEG analysis and evoked potentials), and EEG-based
pro- and anti-convulsant evaluation. 

During his 19 years at Cephalon, Inc., he designed and supervised neurophysiological and pharmacological studies involving numerous disease areas, including evaluation of neuroprotection by trophic agents, free radical inhibitors, kinase inhibitors, and other compounds in neuropathy, neurodegeneration, and motor neuron disease models.  He has also elucidated mechanisms of action of proprietary analgesic agents and utilized evoked potentials for evaluating functional impairment in models of cognitive disorders such as schizophrenia.  He built and ran Cephalon’s preclinical sleep research laboratory, and studied the actions of dopaminergic agents and other drugs in sleep / wake and convulsant activity. He was a discovery team member for several sleep and wake enhancing and psychostimulant agents, including an H3-receptor inverse agonist (irdabisant) currently in clinical development.

Dr. Gruner received his B.A. from UCSD and Ph.D. at Purdue Univ., where he investigated the role of the cerebellum in motor control. As a postdoctoral fellow and later Research Asst. Professor in the Dept. of Neurosurgery at NYU, he designed stimulation systems for paralyzed muscle, was involved in experiments elucidating the role of synapsin phosphorylation in synaptic vesicle release, and carried out electrophysiological and behavioral studies to evaluate treatment efficacy using the spinal cord injury model he helped develop at NYU.  Dr. Gruner is author / co-author on over 40 publications and 1 patent in various areas of neurophysiology.  

melior

                                                    melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE             

   Amy DiCamillo

   Director of Scientific Operations

   Amy DiCamillo is Director of Scientific Operations and is responsible for
   managing multiple research projects.  Amy has 19 years experience in the
   Pharmaceutical industry,  and has acquired considerable expertise in preclinical
   drug discovery and development, mainly in CNS behavioral models.  Amy
   passionately strives for excellence and believes that attention to detail is a critical
   component for producing quality data.  She has worked  to develop, validate, and
   optimize behavior assays for the drug discovery environment  under these
   guiding principles.

Prior to joining Melior Discovery, Amy was a Research Scientist at Cephalon, Inc., where she worked in CNS biology developing in vivo animal models for cognition, anxiety/depression, locomotor activity, and pain.  Amy received her M.S. from the West Chester University of PA where she studied the locomotor effects of Modafinil in MPTP mice while working full-time at Cephalon.  During her 19 years in drug discovery, Amy has authored or coauthored over 20 peer reviewed articles or scientific meeting presentations.  Amy enjoys developing new animal behavior models and troubleshooting the challenges that are often posed in the process.  When not working she also enjoys spending time with her family and releasing energy through zumba and step aerobics classes.

Amy DiCamillo is the key contact for discussing in vivo behavioral models.

 

melior        

                        melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE                       
  Weina Cong, PhD
  Director of Cardiovascular & Metabolic Disease

  Dr. Cong has 12 years experience in metabolic diseases including diabetes,
  obesity, fatty liver disease, and NASH.  She has authored\co-authored over 20
  peer-reviewed articles.

 

  Dr. Cong received her Ph.D. in pharmacology from the Peking Union Medical
  College, China.  During this time, she focused on preclinical pharmacology
studies for metabolic disorders and gained extensive experience on various animal models of metabolic diseases. Subsequently, she conducted her postdoctoral training at the Hospital for Sick Children in Canada during which she investigated the mechanisms of hyperlipidemia.   From 2010 through 2015, as a research fellow, Dr. Cong continued her research experience on metabolic diseases at the Metabolism Unit of National Institute on Aging, USA.  During this time, Dr. Cong also did extensive studies on metabolic alterations in neurodegenerative diseases including Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. Discovering endocrine-modulating compounds for metabolic dysfunctions in neurodegeneration was also one of her specialties.  

 

Recently, Dr. Cong joined Melior Discovery.  She truly believes in our mission and drug repositioning strategy and wants to achieve excellence in preclinical pharmacology of drug discovery at Melior Discovery.  In addition to work, Dr. Cong enjoys cooking and nature.

 

 

melior                       

                        melior melior discovery phenotypic screening drug repositioning repurposing rescuing in vivo efficacy models indications discovery exton pennsylvania theraTRACE                       
 Erin Davis
 Director of Lab Operations

Erin has been with Melior Discovery since 2008.  She came to Melior with several years of experience in both preclinical and clinical fields of research.  She has 10+ years of experience in the field of pharmaceutical research encompassing Pain and Inflammation, Cardiovascular, Gastrointestinal and Neurodegenerative diseases.  Erin has helped developed animal models for pre-clinical testing and has broad experience with in vivo assays, analysis of data, interpretation of results, and presenting information to peers and management.

 

 

melior        

            

 

 

               

 

 

Back to top of page